ABBV-383
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Arms / Cohorts
Experimental Arm A:ABBV-383 + Pomalidomide + Dexamethasone
Accepting patients
Experimental Arm B:ABBV-383 + Lenalidomide + Dexamethasone
Accepting patients
Experimental Arm C:ABBV-383 + Daratumumab + Dexamethasone
Accepting patients
Experimental Arm D:ABBV-383 + Nirogacestat
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.